Targeting EZH2 and PRC2 dependence as novel anticancer therapy

Area of Science:

• Epigenetics and Gene Regulation
• Cancer Biology
• Pharmacology

Background:

• Chromatin modification is key to cellular identity and gene expression.
• Polycomb repressive complex 2 (PRC2) regulates histone methylation (H3K27) and is vital in hematopoiesis.
• EZH2, the catalytic subunit of PRC2, is implicated in B-cell lymphomagenesis via gain-of-function mutations and overexpression.

Purpose of the Study:

• To review recent strategies for inhibiting PRC2, focusing on small-molecule inhibitors of EZH2 and EZH1.
• To explore the functional crosstalk of PRC2 with other epigenetic factors and its role in cancer.
• To discuss EZH2 mutations as predictors of PRC2 inhibitor sensitivity and potential toxicities.

Main Methods:

• Literature review of recent studies on PRC2 inhibitors.
• Analysis of EZH2/1 small-molecule inhibitors.
• Discussion of genetic alterations (e.g., SNF5 inactivation, UTX mutation) conferring PRC2 dependence.
• Examination of EZH2 somatic mutations in B-cell lymphomas and other epigenetic regulators.

Main Results:

• Development of specific and potent small-molecule inhibitors for EZH2 and EZH1.
• Identification of functional crosstalk between PRC2 and other epigenetic regulators.
• Certain genetic events (e.g., SNF5, UTX mutations) enhance sensitivity to PRC2 inhibition.
• EZH2 mutations serve as molecular predictors for PRC2 inhibitor efficacy.

Conclusions:

• PRC2 inhibition is a promising therapeutic strategy for genetically defined hematologic malignancies.
• Understanding EZH2 mutations and epigenetic dependencies can guide personalized cancer therapy.
• Potential toxicities of EZH2/1 inhibition require careful consideration in specific biological and genetic contexts.
• PRC2 inhibition may extend to a wider range of human cancers with similar genetic/epigenetic profiles.